Competitive inhibitors of IDO are currently being tested in clinical trials in patients with solid cancer, including melanoma, with the aim of enhancing the efficacy of conventional chemotherapy, vaccines, or checkpoint inhibitors [156]. This evidence concerns the gene IDO1 and melanoma.